Oncofertility

Last updated
Placing ovarian tissue strips into the preserving solution Petefeszekszovet-csikok fagyaszto oldatba helyezese.jpg
Placing ovarian tissue strips into the preserving solution

Oncofertility is a subfield that bridges oncology and reproductive research to explore and expand options for the reproductive future of cancer survivors. The name was coined in 2006 by Teresa K. Woodruff at the Oncofertility Consortium.

Contents

Cancer treatments, such as chemotherapy, radiation, and surgery, may destroy a person's ability to have children later in life, and oncofertility research focuses on increasing fertility preservation options. With 10% of cancer patients being younger than age 40, this issue affects more than 135,000 people in the United States each year. As cancer survivorship increases, the preservation of fertility in women, men, and children becomes a critically important topic to patients and their families. The ability to easily preserve fertility prior to cancer treatment can provide hope at the time of diagnosis for families later in life. Oncofertility also incorporates reproductive issues after cancer treatment, such as family planning, complex contraception, hormonal management throughout survivorship, surrogacy, and adoption.

Fertility options for men

Established fertility preservation options for men include sperm banking, in which a semen sample is produced, frozen, and stored for future use, [1] and testicular sperm extraction, during which sperm is retrieved directly from the testes through a short surgical procedure and frozen. [ citation needed ]

Experimental options include testicular tissue banking when testicular tissue is surgically removed and frozen. Scientists are developing methods to use this tissue for fertility preservation in males. [ citation needed ]

Men who do not preserve their fertility prior to cancer treatment may have children through donor sperm using sperm from a known or anonymous donor to achieve a pregnancy with a female partner using assisted reproductive technologies or Adoption by permanently assuming all rights and responsibilities of a child through a legal process.[ citation needed ]

Fertility options for women

Cryopreserving ovarian tissue strips Petefeszekszovet-csikok fagyasztva tarolasa.jpg
Cryopreserving ovarian tissue strips

Options for women to have children after cancer have increased significantly in recent years. [2] Women should be counseled on established options such as embryo banking in which hormonal stimulation causes the production of multiple eggs, which are removed, fertilized by sperm, and frozen for future use, and egg banking in which hormonal stimulation causes the production of multiple eggs, which are removed and frozen for storage and future use, and ovarian transposition (surgically moving the ovaries to a different part of the body) and ovarian shielding (physically shielding the ovaries from the area receiving radiation). [3]

Experimental techniques include ovarian tissue banking in which an ovary is surgically removed and frozen to be transplanted back into the woman when she is ready to have children. Scientists are also working on ways to mature undeveloped eggs from this ovarian tissue. [ citation needed ]

After sterilizing cancer treatment, permanent damage to the uterus could be sustained. [4] A woman can also choose surrogacy (when a woman carries a pregnancy for another woman or couple) or adoption. [ citation needed ]

Recent efforts also investigate the implications of a cancer diagnosis during pregnancy.[ citation needed ]

Fertility options for children

Prepubescent children have fewer options to preserve fertility than adults. [5] These include testicular sperm extraction for males and ovarian tissue banking for females.

Fertility preservation costs may be prohibitive for young patients and multiple organizations now provide methods to reduce costs for patients. [6] These include Fertile Hope and Fertile Action.[ citation needed ]

The Supreme Court of the United States addressed the Social Security implications of oncofertility in March 2012 with Astrue v. Capato .[ citation needed ]

Research also investigates ethical issues in oncofertility, such as the decision-making process for adolescent children and their families. [7]

Related Research Articles

<span class="mw-page-title-main">In vitro fertilisation</span> Assisted reproductive technology procedure

In vitro fertilisation (IVF) is a process of fertilisation where an egg is combined with sperm in vitro. The process involves monitoring and stimulating a woman's ovulatory process, removing an ovum or ova from her ovaries and letting sperm fertilise them in a culture medium in a laboratory. After the fertilised egg (zygote) undergoes embryo culture for 2–6 days, it is transferred by catheter into the uterus, with the intention of establishing a successful pregnancy.

Infertility is the inability of a person, animal or plant to reproduce by natural means. It is usually not the natural state of a healthy adult, except notably among certain eusocial species. It is the normal state of a human child or other young offspring, because they have not undergone puberty, which is the body's start of reproductive capacity.

<span class="mw-page-title-main">Assisted reproductive technology</span> Methods to achieve pregnancy by artificial or partially artificial means

Assisted reproductive technology (ART) includes medical procedures used primarily to address infertility. This subject involves procedures such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), cryopreservation of gametes or embryos, and/or the use of fertility medication. When used to address infertility, ART may also be referred to as fertility treatment. ART mainly belongs to the field of reproductive endocrinology and infertility. Some forms of ART may be used with regard to fertile couples for genetic purpose. ART may also be used in surrogacy arrangements, although not all surrogacy arrangements involve ART. The existence of sterility will not always require ART to be the first option to consider, as there are occasions when its cause is a mild disorder that can be solved with more conventional treatments or with behaviors based on promoting health and reproductive habits.

Fertility medications, also known as fertility drugs, are medications which enhance reproductive fertility. For women, fertility medication is used to stimulate follicle development of the ovary. There are very few fertility medication options available for men.

<span class="mw-page-title-main">Testicular sperm extraction</span>

Testicular sperm extraction (TESE) is a surgical procedure in which a small portion of tissue is removed from the testicle and any viable sperm cells from that tissue are extracted for use in further procedures, most commonly intracytoplasmic sperm injection (ICSI) as part of in vitro fertilisation (IVF). TESE is often recommended to patients who cannot produce sperm by ejaculation due to azoospermia.

<span class="mw-page-title-main">Oocyte cryopreservation</span> Procedure to preserve a womans eggs (oocytes)

Oocyte cryopreservation is a procedure to preserve a woman's eggs (oocytes). This technique has been used to enable women to postpone pregnancy to a later date – whether for medical or social reasons. Several studies have shown that most infertility problems are due to germ cell deterioration related to aging. The intention of the procedure is that the woman may choose to have the eggs thawed, fertilized, and transferred to the uterus as embryos to facilitate a pregnancy in the future. The procedure's success rate varies depending on the age of the woman, with odds being higher in younger, adult women.

<span class="mw-page-title-main">In vitro maturation</span> Artificial maturation of harvested immature egg cells

In vitro maturation (IVM) is the technique of letting the contents of ovarian follicles and the oocytes inside mature in vitro. It can be offered to women with infertility problems, combined with In Vitro Fertilization (IVF), offering women pregnancy without ovarian stimulation.

<span class="mw-page-title-main">Oncofertility Consortium</span> International research group

The Oncofertility Consortium is an international, multi-institutional group that assesses the impact of cancer and its treatment on reproductive health. Founded by Dr. Teresa Woodruff in 2007, its primary mission is to expand fertility options for cancer survivors. It has since expanded this mission to include non-oncologic conditions that affect fertility, including differences of sex development, gender-affirming treatment, and transfusion-dependent thalassemia.

Fertility preservation is the effort to help cancer patients retain their fertility, or ability to procreate. Research into how cancer, ageing and other health conditions effect reproductive health and preservation options are growing. Specifically sparked in part by the increase in the survival rate of cancer patients.

The Genetics & IVF Institute (GIVF) is an international provider of infertility and genetics services and products, and also engages in biomedical research in these fields. The Institute was founded in 1984 by Dr. Joseph D. Schulman and associates. GIVF headquarters are in Fairfax, VA, US, and its facilities include locations in Pennsylvania, Minnesota, California, and Texas in the United States, as well as in China, Mexico, and several other countries.

<span class="mw-page-title-main">Ovarian torsion</span> Medical condition

Ovarian torsion (OT) or adnexal torsion is an abnormal condition where an ovary twists on its attachment to other structures, such that blood flow is decreased. Symptoms typically include pelvic pain on one side. While classically the pain is sudden in onset, this is not always the case. Other symptoms may include nausea. Complications may include infection, bleeding, or infertility.

Reproductive surgery is surgery in the field of reproductive medicine. It can be used for contraception, e.g. in vasectomy, wherein the vasa deferentia of a male are severed, but is also used plentifully in assisted reproductive technology. Reproductive surgery is generally divided into three categories: surgery for infertility, in vitro fertilization, and fertility preservation.

Ovarian tissue cryopreservation is cryopreservation of tissue of the ovary of a female.

Endometriosis and its complications are a major cause of female infertility. Endometriosis is a dysfunction characterized by the migration of endometrial tissue to areas outside of the endometrium of the uterus. The most common places to find stray tissue are on ovaries and fallopian tubes, followed by other organs in the lower abdominal cavity such as the bladder and intestines. Typically, the endometrial tissue adheres to the exteriors of the organs, and then creates attachments of scar tissue called adhesions that can join adjacent organs together. The endometrial tissue and the adhesions can block a fallopian tube and prevent the meeting of ovum and sperm cells, or otherwise interfere with fertilization, implantation and, rarely, the carrying of the fetus to term.

Ovarian follicle activation can be defined as primordial follicles in the ovary moving from a quiescent (inactive) to a growing phase. The primordial follicle in the ovary is what makes up the “pool” of follicles that will be induced to enter growth and developmental changes that change them into pre-ovulatory follicles, ready to be released during ovulation. The process of development from a primordial follicle to a pre-ovulatory follicle is called folliculogenesis.

Cancer in adolescents and young adults is cancer which occurs in those between the ages of 15 and 39. This occurs in about 70,000 people a year in the United States—accounting for about 5 percent of cancers. This is about six times the number of cancers diagnosed in children ages 0–14. Globally, nearly 1 million young adults between the ages of 20 and 39 were diagnosed with cancer in 2012, and more than 350,000 people in this age range died from cancer.

Cryopreservation of testicular tissue is an experimental method being used to preserve fertility in pre-pubescent males, or males who cannot produce sperm, to allow them the option of having biological children.

<span class="mw-page-title-main">Artificial ovary</span>

An artificial ovary is a potential fertility preservation treatment that aims to mimic the function of the natural ovary.

<span class="mw-page-title-main">LGBT reproduction</span> Theoretical biological reproduction by LGBT people

LGBT reproduction refers to lesbian, gay, bisexual, and transgender (LGBT) people having biological children by means of assisted reproductive technology. It is distinct from LGBT parenting, which is a broader cultural phenomenon including LGBT adoption. In recent decades, developmental biologists have been researching and developing techniques to facilitate same-sex reproduction.

<span class="mw-page-title-main">Side effects of radiotherapy on fertility</span>

The side effects of radiotherapy on fertility are a growing concern to patients undergoing radiotherapy as cancer treatments. Radiotherapy is essential for certain cancer treatments and often is the first point of call for patients. Radiation can be divided into two categories: ionising radiation (IR) and non-ionising radiation (NIR). IR is more dangerous than NIR and a source of this radiation is X-rays used in medical procedures, for example in radiotherapy.

References

  1. Sheth, Kunj R.; Sharma, Vidit; Helfand, Brian T.; Cashy, John; Smith, Kristin; Hedges, Jason C.; Köhler, Tobias S.; Woodruff, Teresa K.; Brannigan, Robert E. (2012). "Improved Fertility Preservation Care for Male Patients with Cancer After Establishment of Formalized Oncofertility Program". The Journal of Urology. 187 (3): 979–86. doi:10.1016/j.juro.2011.10.154. PMID   22264454.
  2. Noyes, Nicole; Knopman, Jaime M.; Long, Kara; Coletta, Jaclyn M.; Abu-Rustum, Nadeem R. (2011). "Fertility considerations in the management of gynecologic malignancies". Gynecologic Oncology. 120 (3): 326–33. doi:10.1016/j.ygyno.2010.09.012. PMID   20943258.
  3. Jungheim, Emily S.; Carson, Kenneth R.; Brown, Douglas (2010). "Counseling and Consenting Women with Cancer on Their Oncofertility Options: A Clinical Perspective". Oncofertility. Cancer Treatment and Research. Vol. 156. pp. 403–12. doi:10.1007/978-1-4419-6518-9_31. ISBN   978-1-4419-6517-2. PMC   3071538 . PMID   20811851.
  4. Griffiths M, Marshall S, Cousins F, Alesi L, Higgins J, Giridharan S, Sarma U, Menkhorst E, Zhou W, Care A, Donoghue J, Holdsworth-Carson S, Rogers P, Dimitriadis E, Gargett C ,Robertson S, Winship A & Hutt K. Radiotherapy exposure directly damages the uterus and causes pregnancy loss. (2023) JCI Insight. 8(6):e163704. doi: 10.1172/jci.insight.163704 PMID: 36946464
  5. Wallace, W. Hamish B. (2011). "Oncofertility and preservation of reproductive capacity in children and young adults". Cancer. 117 (10 Suppl): 2301–10. doi: 10.1002/cncr.26045 . PMID   21523750.
  6. King, Rosalind Berkowitz (2010). "Perspectives on Oncofertility from Demography and Economics". Oncofertility. Cancer Treatment and Research. Vol. 156. pp. 371–9. doi:10.1007/978-1-4419-6518-9_28. ISBN   978-1-4419-6517-2. PMC   3071554 . PMID   20811848.
  7. Galvin, Kathleen M.; Clayman, Marla L. (2010). "Whose Future Is It? Ethical Family Decision Making About Daughters' Treatment in the Oncofertility Context". Oncofertility. Cancer Treatment and Research. Vol. 156. pp. 429–45. doi:10.1007/978-1-4419-6518-9_33. ISBN   978-1-4419-6517-2. PMC   3086488 . PMID   20811853.